DGIdb - CARMUSTINE Drug Record

CARMUSTINE chembl:CHEMBL513 ApprovedAntineoplasticImmunotherapy

Alternate Names:

BCNU
GLIADEL
SRI-1720
CARMUSTINE
NSC-409962
FDA-0345
DTI-015
SK-27702
BICNU
CARUSTINE®
BISCHLOROETHYL NITROSOUREA
N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA
BICNU®
BIS-CHLOROETHYLNITROSOUREA
CARMUSTINUM
CARMUSTINA
BICNU (TN)
pubchem.compound:2578
drugbank:00262
chembl:CHEMBL513
rxcui:2105
chemidplus:154-93-8

Drug Info:

Drug Class	antineoplastic agents
Year of Approval	1977
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent

(5 More Sources)

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Go et al., 1997, Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro., Clin. Exp. Metastasis
Gomez-Manzano et al., 2001, Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU., Int. J. Oncol.
Powell et al., 1987, Effect of inhibition of glutathione reductase by carmustine on central nervous system oxygen toxicity., J. Pharmacol. Exp. Ther.
Doroshenko et al., 2004, The glutathione reductase inhibitor carmustine induces an influx of Ca2+ in PC12 cells., Eur. J. Pharmacol.
Vallyathan et al., 1992, Enhanced generation of free radicals from phagocytes induced by mineral dusts., Am. J. Respir. Cell Mol. Biol.
Jopperi-Davis et al., 2004, Compartmental inhibition of hepatic glutathione reductase activities by 1,3-bis(2-chloroethyl)-N-nitrosourea (BCNU) in Sprague-Dawley and Fischer-344 rats., Toxicol. Lett.
Akella et al., Pyridine nucleotide flux and glutathione oxidation in the cultured rat conceptus., Reprod. Toxicol.
Kirsch et al., 2002, Accumulation of glutathione disulfide mediates NF-kappaB activation during immune stimulation with CpG DNA., Antisense Nucleic Acid Drug Dev.
Puglia et al., 1984, Inhibition of cellular antioxidants: a possible mechanism of toxic cell injury., Environ. Health Perspect.
Brodie et al., 1992, Glutathione disulfide reduction in tumor mitochondria after t-butyl hydroperoxide treatment., Chem. Biol. Interact.
Esteller et al., 2000, Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents., N. Engl. J. Med.
Sagone AL Jr et al., 1979, The effect of BCNU and adriamycin on normal and G6PD deficient erythrocytes., Am J Hematol

CARMUSTINE GSR

Interaction Score: 4.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name polifeprosan 20/carmustine,Gliadel

Novel drug target Established target

Mechanism of Interaction Glutathione reductase inhibitor

PMIDs:
3806383 15321730 1312851 15104113 10378469 12477282 6094175 1394620

Sources:
TdgClinicalTrial ChemblInteractions TEND
CARMUSTINE E2F1

Interaction Score: 0.7

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11445852

Sources:
NCI
CARMUSTINE MGMT

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11070098

Sources:
CIViC
CARMUSTINE PLAU

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9219734

Sources:
NCI
CARMUSTINE G6PD

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
539595

Sources:
PharmGKB
CARMUSTINE CYP2C9

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
CARMUSTINE CYP2C19

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
CARMUSTINE CYP1A2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
CARMUSTINE CYP2D6

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
CARMUSTINE ALDH1A1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CARMUSTINE CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC

TEND: CARMUSTINE
- Version: 01-August-2011
Alternate Names:

CARMUSTINE Primary Drug Name

Drug Info:

Year of Approval 1977

Drug Class antineoplastic agents

Publications:
TdgClinicalTrial: CARMUSTINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: BCNU

Version: 14-September-2017

Alternate Names:

C349 NCI drug code

Drug Info:

Publications:

Go et al., 1997, Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro., Clin. Exp. Metastasis

Gomez-Manzano et al., 2001, Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU., Int. J. Oncol.

DTC: CARMUSTINE
- Version: 02-September-2020
Alternate Names:

CHEMBL513 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
PharmGKB: carmustine
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

Sagone AL Jr et al., 1979, The effect of BCNU and adriamycin on normal and G6PD deficient erythrocytes., Am J Hematol
CIViC: CARMUSTINE
- Version: 14-September-2020
Alternate Names:

Drug Info:

Publications:

Esteller et al., 2000, Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents., N. Engl. J. Med.
TTD: DTI-015
- Version: 2020.06.01
Alternate Names:

D01OXI TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL513
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL513
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Trial Name	polifeprosan 20/carmustine,Gliadel
Novel drug target	Established target
Mechanism of Interaction	Glutathione reductase inhibitor

CARMUSTINE Drug Record

CARMUSTINE chembl:CHEMBL513 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name polifeprosan 20/carmustine,Gliadel Novel drug target Established target Mechanism of Interaction Glutathione reductase inhibitor

PMIDs: 3806383 15321730 1312851 15104113 10378469 12477282 6094175 1394620

Sources: TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11445852

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11070098

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9219734

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 539595

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

TEND: CARMUSTINE

Alternate Names: CARMUSTINE Primary Drug Name

Drug Info: Year of Approval 1977 Drug Class antineoplastic agents

Publications:

TdgClinicalTrial: CARMUSTINE

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class Small Molecule FDA Approval approved

Publications:

NCI: BCNU

Alternate Names: C349 NCI drug code

Drug Info:

DTC: CARMUSTINE

Alternate Names: CHEMBL513 ChEMBL Drug ID

Drug Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

PharmGKB: carmustine

Alternate Names:

Drug Info:

Publications: Sagone AL Jr et al., 1979, The effect of BCNU and adriamycin on normal and G6PD deficient erythrocytes., Am J Hematol

CIViC: CARMUSTINE

Alternate Names:

Drug Info:

Publications: Esteller et al., 2000, Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents., N. Engl. J. Med.

TTD: DTI-015

Alternate Names: D01OXI TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL513

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name polifeprosan 20/carmustine,Gliadel

Novel drug target Established target

Mechanism of Interaction Glutathione reductase inhibitor

PMIDs:
3806383 15321730 1312851 15104113 10378469 12477282 6094175 1394620

Sources:
TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality:

n/a

PMIDs:
11445852

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11070098

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
9219734

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
539595

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Alternate Names:

CARMUSTINE Primary Drug Name

Drug Info:

Year of Approval 1977

Drug Class antineoplastic agents

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Alternate Names:

C349 NCI drug code

Alternate Names:

CHEMBL513 ChEMBL Drug ID

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Publications:

Sagone AL Jr et al., 1979, The effect of BCNU and adriamycin on normal and G6PD deficient erythrocytes., Am J Hematol

Publications:

Esteller et al., 2000, Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents., N. Engl. J. Med.

Alternate Names:

D01OXI TTD Drug ID